CARA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CARA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cara Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $3.06 Mil. Cara Therapeutics's Revenue for the three months ended in Dec. 2023 was $3.00 Mil. Hence, Cara Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 92.89.
The historical rank and industry rank for Cara Therapeutics's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Cara Therapeutics's highest Days Sales Outstanding was 89.01. The lowest was 28.42. And the median was 40.43.
Cara Therapeutics's Days Sales Outstanding declined from Dec. 2022 (180.25) to Dec. 2023 (92.89).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
The historical data trend for Cara Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cara Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cara Therapeutics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Cara Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (3.26 | + | 2.765) | / | 2 ) | / | 20.968 | * | 365 |
= | 3.0125 | / | 20.968 | * | 365 | ||||
= | 52.44 |
Cara Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding (Q: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Sep. 2023 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (3.351 | + | 2.765) | / | 2 ) | / | 3.004 | * | 365 / 4 |
= | 3.058 | / | 3.004 | * | 365 / 4 | ||||
= | 92.89 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cara Therapeutics (NAS:CARA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Cara Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher Posner | director | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902 |
Helen M Boudreau | director | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Joana Goncalves | officer: Chief Medical Officer | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902 |
Scott Terrillion | officer: Sec'y; Chief Compliance & G.C. | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902 |
Menzaghi Frederique Ph.d. | officer: VP-Research & Development | C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484 |
Moltke Lisa Von | director | C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139 |
Martin Vogelbaum | director | 675 ALMANOR AVE, SUNNYVALE CA 94085 |
Ryan D Maynard | officer: Chief Financial Officer | RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080 |
Csl Ltd | 10 percent owner | |
Jeffrey L. Ives | director | C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484 |
Bains Harrison M Jr | director | |
Thomas Charles Reilly | officer: Chief Financial Officer | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902 |
Vifor Fresenius Medical Care Renal Pharma Ltd. | 10 percent owner | RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014 |
Vifor (international) Ltd | 10 percent owner | RECHENSTRASSE 37, ST. GALLEN V8 9000 |
Vifor Pharma Ltd. | 10 percent owner | UNTERMATTWEG 8, BERNE V8 CH-3027 |
From GuruFocus
By sperokesalga 05-01-2023
By PurpleRose 08-19-2022
By GuruFocusNews 06-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.